{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:48:35Z","timestamp":1785890915718,"version":"3.56.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vascn.2025.108387","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:28:01Z","timestamp":1752766081000},"page":"108387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Legacy hERG study data in contemporary integrated risk assessments \u2013 mitigating the risk of protocol and positive control article differences"],"prefix":"10.1016","volume":"135","author":[{"given":"Richard W.","family":"Daniels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Abernathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek D.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Brimecombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2025.108387_bb0005","series-title":"ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.vascn.2025.108387_bb0010","article-title":"ICH E14\/S7B implementation working group - clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential","author":"Anonymous.","year":"2022","journal-title":"Questions and Answers."},{"key":"10.1016\/j.vascn.2025.108387_bb0015","series-title":"Variability of manual patch clamp hERG data generated using standardized protocols and following ICH S7B Q&a 2.1 best practices. Poster #035-A","author":"Baron","year":"2024"},{"issue":"4","key":"10.1016\/j.vascn.2025.108387_bb0020","first-page":"15","article-title":"Drug-induced long QT syndrome: Is HERG the root of all evil","volume":"7","author":"Brown","year":"2000","journal-title":"Pharmaceutical News"},{"issue":"1","key":"10.1016\/j.vascn.2025.108387_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/01.RES.72.1.75","article-title":"Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide","volume":"72","author":"Jurkiewicz","year":"1993","journal-title":"Circulation Research"},{"key":"10.1016\/j.vascn.2025.108387_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107524","article-title":"Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions","volume":"128","author":"Leishman","year":"2024","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2025.108387_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"issue":"2","key":"10.1016\/j.vascn.2025.108387_bb0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel","volume":"81","author":"Sanguinetti","year":"1995","journal-title":"Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.vascn.2025.108387_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s003950050236","article-title":"Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs","volume":"93","author":"Weirich","year":"1998","journal-title":"Basic Research in Cardiology"},{"key":"10.1016\/j.vascn.2025.108387_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.966331","article-title":"Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system","volume":"9","author":"Wu","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10.1016\/j.vascn.2025.108387_bb0055","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687192500807X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687192500807X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:19:50Z","timestamp":1760213990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687192500807X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":11,"alternative-id":["S105687192500807X"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2025.108387","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Legacy hERG study data in contemporary integrated risk assessments \u2013 mitigating the risk of protocol and positive control article differences","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2025.108387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108387"}}